FG Nexus liquidated crypto reserves: Nasdaq-listed company exited Ethereum with a $45 million loss
The strategy of corporate Ethereum accumulation on the public market has suffered another fiasco. FG Nexus, whose shares are traded on the Nasdaq exchange, has fully sold off its digital assets and officially wound down its ETH program, which lasted less than a year. This decision is a clear signal that even institutional players are not immune to volatility and errors in market entry timing.
At the peak of its portfolio, the company managed 50,000 ETH, which at that time represented a significant position for a non-crypto firm. However, the outcome proved disappointing. In the first half of the year, the sale of coins brought FG Nexus $60.96 million in cash, with an additional $14.98 million added in July. Despite these inflows, the net loss from the entire operation reached $45.2 million. Income from staking, often touted as a passive benefit, amounted to only a modest $144,000 — a drop in the ocean compared to the losses incurred.
Why this matters for the market
The liquidation of such a volume of assets is not just a corporate story. It is a demonstration that classic financial companies entering the crypto market often underestimate its cyclical nature. Buying ETH during a period of euphoria and being forced to sell during a downturn is a typical scenario for those without experience working with digital assets.
Now, FG Nexus plans to redistribute all of its freed-up capital into real estate. This is a classic retreat to a "safe haven" after an unsuccessful experiment. However, for observers, it is more of a confirmation: corporate treasuries must either deeply immerse themselves in the specifics of the crypto market or not risk shareholder funds without hedging.
My view: FG Nexus's exit is not a death sentence for Ethereum, but rather a lesson in risk management. The $45 million loss with a peak position of 50,000 ETH shows that the company likely entered the asset at local highs and did not use tools to insure against drawdowns. Until such players emerge, the market will remain a field for patient professionals, not for public corporations with a short planning horizon.